Cargando…
Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456793/ https://www.ncbi.nlm.nih.gov/pubmed/28157683 http://dx.doi.org/10.1136/gutjnl-2016-312444corr1 |
| _version_ | 1783409811530973184 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6456793 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-64567932019-04-26 Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort Gut Correction BMJ Publishing Group 2016-12 /pmc/articles/PMC6456793/ /pubmed/28157683 http://dx.doi.org/10.1136/gutjnl-2016-312444corr1 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ |
| spellingShingle | Correction Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort |
| title | Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort |
| title_full | Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort |
| title_fullStr | Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort |
| title_full_unstemmed | Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort |
| title_short | Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort |
| title_sort | erratum: daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with hcv infection and advanced liver disease in a real-world cohort |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456793/ https://www.ncbi.nlm.nih.gov/pubmed/28157683 http://dx.doi.org/10.1136/gutjnl-2016-312444corr1 |